The first participant has been dosed in a CEPI-backed Phase 1 trial of Moderna's investigational vaccine against Bundibugyo virus, marking rapid progress in the global effort to combat the deadly Ebola outbreak in DRC. Read more: cepi.net/modernas-bun...

The first participant has been dosed in a CEPI-backed Phase 1 trial of Moderna's investigational vaccine against Bundibugyo virus, marking rapid progress in the global effort to combat the deadly Ebola outbreak in DRC. Read more: cepi.net/modernas-bun...

🚨Last chance to apply! @cepi.net is seeking technical partners to support faster outbreak response by helping ensure critical biospecimens are available when needed. Apply by Aug 12: https://bit.ly/4hHQL5X #VaccinesWork

The Bundibugyo Ebola epidemic in the Democratic Republic of the Congo has passed a tragic milestone. Just 11 weeks after it was declared, the outbreak has reached 3,748 confirmed cases, making it the second-largest Ebola outbreak in history and the fastest-growing ever recorded.

CEPI's July newsletter is now available 🗞️ Explore the latest progress in the fight against the fastest-growing Ebola outbreak on record, along with new CEPI 3.0 campaign resources, open Calls for Proposals and lots more ⬇️

As Bundibugyo virus death toll mounts, hope is on the horizon

A tragic milestone was reached this month as the Bundibugyo ebolavirus outbreak – the fastest-growing Ebola outbreak on record - continues to escalate, with more than 1,400 deaths now recorded. As the...

linkedin.com

With the Bundibugyo outbreak the fastest-growing Ebola epidemic on record, CEPI is providing up to $8.5m to Hilleman Laboratories, a joint MSD-Wellcome Trust venture, to accelerate development and manufacture of an rVSV vaccine candidate for clinical trials. cepi.net/hilleman-lab...

Hilleman Laboratories to develop and produce CEPI-backed Bundibugyo ebolavirus vaccine doses for clinical trials

No vaccine is currently approved against the virus. The rVSV vaccine candidate could become an important tool for Bundibugyo outbreak control and response.

cepi.net

A powerful affirmation from Institut Pasteur de Dakar CEO Dr. Ibrahima Socé Fall, one of CEPI's key manufacturing partners, on the need for an organisation like CEPI and why continued investment in CEPI 3.0 is critical for our collective global health security ⬇️

The first volunteer has been vaccinated with the @ox.ac.uk's Bundibugyo ebolavirus vaccine candidate in a CEPI-backed clinical trial as efforts ramp up to contain a fast-spreading and deadly outbreak affecting the Democratic Republic of the Congo. Read more: www.ox.ac.uk/news/2026-07...

ICYMI: a CEPI-backed vaccine candidate developed by the University of Oxford became the first vaccine targeting Bundibugyo virus to enter Phase I trials, just 57 days after the WHO declared the outbreak a public health emergency. The Independent reports ⬇️

Oxford University begins human trials of new Ebola vaccine

The jab could be ready to send to the Democratic Republic of Congo within weeks

independent.co.uk

In our new blog, CEPI's Chief Scientific Writer Kate Kelland asked Aurélia Nguyen, CEPI’s Deputy CEO, to explain how CEPI is supporting the global response to the Bundibugyo outbreak and how that work aligns with the 100 Days Mission. Read the new Q&A to learn more: cepi.net/bundibugyo-a...

Bundibugyo and the 100 Days Mission: Preparedness, Readiness and Response

Aurélia Nguyen, CEPI’s Deputy CEO, explains how CEPI is supporting the global response to the Bundibugyo outbreak and how that work aligns with the 100 Days Mission.

cepi.net

CEPI has recently published its 2025 Annual Progress Report – a timely reflection of a year that reinforced why epidemic and pandemic preparedness is more important than ever. Read it here: static.cepi.net/downloads/20...

Our recent Innovations for Impact story takes a closer look at this clinical trial site in Bauchi, Nigeria, and the impact it is already helping to deliver in the region. Read it here ➡️ cepi.net/innovations-...

Outbreak ready, research ready: strengthening West Africa’s research ecosystem

CEPI’s Research Preparedness Programme is strengthening clinical trial infrastructure, systems and skills at frontline sites across West Africa.

cepi.net

MRC Unit The Gambia at LSHTM@mrcunitgambia.bsky.social · last mo.

We are excited to share the launch of the Abubakar Tafawa Balewa University Teaching Hospital clinical trial centre! Proud to have partnered with @cepi.net to strengthen #ClinicalTrials capacity & #EpidemicPreparedness efforts in #WestAfrica. #ClinicalResearch #Partnerships #ResearchCapacity

We are excited to share the launch of the Abubakar Tafawa Balewa University Teaching Hospital clinical trial centre! Proud to have partnered with @cepi.net to strengthen #ClinicalTrials capacity & #EpidemicPreparedness efforts in #WestAfrica. #ClinicalResearch #Partnerships #ResearchCapacity

CEPI has announced updates to its Scientific Advisory Committee, an external expert group providing independent scientific guidance across R&D programmes and outbreak preparedness activities. More: cepi.net/new-experts-...

New experts appointed to CEPI’s Scientific Advisory Committee

CEPI has announced updates to its Scientific Advisory Committee (SAC), an external expert group providing independent scientific guidance across R&D programmes and outbreak preparedness activities.

cepi.net

CEPI's latest newsletter is now available 🗞️ Dive in to explore the latest in epidemic and pandemic preparedness, including CEPI's Global Vaccine Manufacturing Summit, new investments to combat the Bundibugyo ebolavirus outbreak, CEPI 3.0 campaign updates and more.

Vaccine manufacturing: the bridge between science and impact

CEPI convened the Global Vaccine Manufacturing Summit 2026 in London, UK, on 17th June. For the first time, financing institutions, vaccine developers, regulators, manufacturers, philanthropies and gl...

linkedin.com

Earlier this month, researchers in our Preclinical Model and Centralised Laboratory Networks met up in Cape Town, South Africa, to discuss how they can strengthen collaboration and make the goal of developing a vaccine in 100 days a reality. Discover more in this Q+A: cepi.net/lab-scientis...

The lab scientists banding together to test new outbreak-busting vaccines

We're using knowledge built from the COVID-19 pandemic to strengthen the networks evaluating vaccine candidates that could fight the next big outbreak.

cepi.net

New funding from CEPI will help take a promising nanoparticle vaccine platform into early clinical development, with the aim of speeding up how we respond to future outbreaks. More ⬇️

CEPI funds next phase of nanoparticle vaccine platform to support rapid outbreak response

New funding will support the continued development of a pioneering vaccine platform.

cepi.net

🔉 CEPI is urgently accelerating the development of three investigational vaccine candidates towards clinical trials in response to the deeply concerning Bundibugyo ebolavirus epidemic. More in the press release ⬇️

CEPI fast-tracks three Bundibugyo ebolavirus vaccine candidates

CEPI funding will advance vaccine candidates towards clinical trials as quickly as possible.

cepi.net

CEPI's latest newsletter is now available! From funding to accelerate clinical develop of three #Bundibugyo virus vaccine candidates to renewed commitments to support CEPI 3.0, a lot has happened over the last month. Catch up: www.linkedin.com/pulse/bundib...

As Bundibugyo virus spreads, CEPI accelerates new vaccine candidates

A rapidly escalating epidemic of Bundibugyo ebolavirus in the Democratic Republic of the Congo and Uganda has triggered public health emergency declarations from both Africa CDC and WHO. This is now t...

linkedin.com

CEPI has launched an urgent Call for Proposals seeking to accelerate early‑stage vaccine candidates against Bundibugyo virus (BDBV). Eligibility and how to apply: cepi.my.site.com/call-for-pro...

CEPI has launched an urgent Call for Proposals seeking to accelerate early‑stage vaccine candidates against Bundibugyo virus (BDBV). Eligibility and how to apply: cepi.my.site.com/call-for-pro...

CEPI's latest newsletter is now available! From funding to accelerate clinical develop of three #Bundibugyo virus vaccine candidates to renewed commitments to support CEPI 3.0, a lot has happened over the last month. Catch up: www.linkedin.com/pulse/bundib...

As Bundibugyo virus spreads, CEPI accelerates new vaccine candidates

A rapidly escalating epidemic of Bundibugyo ebolavirus in the Democratic Republic of the Congo and Uganda has triggered public health emergency declarations from both Africa CDC and WHO. This is now t...

linkedin.com

CEPI's latest newsletter is now available! From funding to accelerate clinical development of three #Bundibugyo virus vaccine candidates to renewed commitments to support CEPI 3.0, a lot has happened over the last month. Catch up: www.linkedin.com/pulse/bundib...

As Bundibugyo virus spreads, CEPI accelerates new vaccine candidates

A rapidly escalating epidemic of Bundibugyo ebolavirus in the Democratic Republic of the Congo and Uganda has triggered public health emergency declarations from both Africa CDC and WHO. This is now t...

linkedin.com

🔉 CEPI is urgently accelerating the development of three investigational vaccine candidates towards clinical trials in response to the deeply concerning Bundibugyo ebolavirus epidemic. More in the press release ⬇️

CEPI fast-tracks three Bundibugyo ebolavirus vaccine candidates

CEPI funding will advance vaccine candidates towards clinical trials as quickly as possible.

cepi.net

The next pandemic could begin anywhere, at any moment. And the risk of a deadly outbreak is only rising. But it doesn’t have to be that way. CEPI 3.0 is our plan to move the world from reactive response to proactive protection.

The @ec.europa.eu announced €73.7m in #HorizonEurope support to @cepi.net for 2026–2027. Part of the #EU’s new Global Health Resilience Initiative, this funding will support vaccine R&D and help strengthen #preparedness when new health threats emerge👇 #WHA79 @florikafinkhooijer.bsky.social

Europe is reinforcing its commitment to a world protected from epidemic and pandemic threats as current outbreaks underscore the persistent risk posed by infectious diseases. Today at #WHA79, the @ec.europa.eu announced €73.7 million commitment to CEPI for 2026 and 2027. 🇪🇺 More: bit.ly/4dxBcdE

Singapore is strengthening global defences against future epidemic and pandemic threats. Today at #WHA79, Singapore pledged US$12 million to support our CEPI 3.0 strategy—a powerful signal of leadership from a global innovation hub. 🇸🇬 More: bit.ly/4dxBcdE

At #WHA79 in Geneva, we were honoured to welcome major new financial commitments from the European Union (€73.7 million) and Singapore (US$12 million) to support our work to transform the world’s ability to prevent and respond to epidemic and pandemic threats.

European Union and Singapore Back CEPI’s Plan to Boost Global Defences Against Epidemic and Pandemic Threats

Major new investments bolster global coalition's five-year plan to develop vaccines against the most dangerous pathogens and transform the world’s ability to tackle epidemic and pandemic threats.

cepi.net

LIVE: watch our official #WHA79 side event entitled: “From Outbreak Response to System Readiness: Building the Global and Regional Capabilities to Stop Pandemic Threats in 100 Days” Click the link to watch in real time 📺 bit.ly/4eReCPm